首页 › 慢性淋巴细胞白血病 › 俄亥俄州 › Cleveland
Cleveland OH 慢性淋巴细胞白血病临床试验
8项针对 慢性淋巴细胞白血病的研究正在 Cleveland及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
招募中3 期
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Hillcrest Hospital Cancer Center, Mayfield Heights · 距离 12 英里
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Hillcrest Hospital Cancer Center, Mayfield Heights · 距离 12 英里
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
招募中3 期
- University Hospitals, Cleveland
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- The Cleveland Clinic Foundation, Cleveland
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
招募中1 期
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Cleveland Clinic, Cleveland
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
招募中3 期
- Cleveland Clinic Main Campus /ID# 271292, Cleveland
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- University Hospitals Cleveland Medical Center, Cleveland
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Columbus, OH28 项研究
- Durham, NC27 项研究
- Washington, DC22 项研究
- Seattle, WA20 项研究
- Rochester, MN19 项研究
- New York City, NY18 项研究
- Houston, TX17 项研究
- Baldwin Park, CA16 项研究
- Milwaukee, WI15 项研究
- Chicago, IL14 项研究
- Cincinnati, OH14 项研究
Cleveland的其他研究
- 非小细胞肺癌43 项研究
- 癌症（所有类型）36 项研究
- 乳腺癌35 项研究
- 前列腺癌34 项研究
- 心力衰竭33 项研究
- 转移性癌症30 项研究
- 卵巢癌30 项研究
- 肺癌26 项研究
- 结直肠癌24 项研究
- 心血管疾病22 项研究
- 子宫内膜癌20 项研究
- 急性髓系白血病20 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。